Tech Company Financing Transactions

Revance Therapeutics Funding Round

Revance Therapeutics closed a $45 million Series E funding round on 6/10/2011. Investors included EW Healthcare Partners, NovaQuest and Pac-Link Bio.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

1222 Demonbreun St. 2000
Nashville, TN 37203
USA

Phone

(510) 742-3400

Website

www.revance.com

Email Address

[email protected]

Overview

Revance (NASDAQ: RVNC) is developing its lead compound, a topical botulinum toxin based on its cutting-edge drug delivery platforms and low molecular weight botulinum toxin. This product leverages Revance's platform technologies to enhance patient tolerability of botulinum toxin.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Mark Foley

        

Chief Financial Officer

Tobin Schilke

        

Chief Operating Officer

Abhay Joshi

        

VP - Bus. Development

Dustin Sjuts

        

VP - Human Resources

Justin Ford

        

Browse more venture capital transactions:

Prev: 6/10/2011: Embedly venture capital transaction
Next: 6/10/2011: Ophthonix venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary